Skip To Main Content
Vice-President Operations on Muck Rack

Vice-President Operations

As seen in: Business Wire
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vice-President

Contact Vice-President, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

First Patient Dosed in New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients Original

|
By Shahid Kamal Ahmad, Vice-President Operations
| Business Wire
First Patient Dosed in New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients TORONTO--(BUSINESS WIRE)--The first patient has been treated in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis.
Open in Who Shared View Duplicates (27) Issue with article?

Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients Original

|
By Shahid Kamal Ahmad, Vice-President Operations
| Business Wire
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics, Inc., ("Vasomune"), a clinical-stage biopharmaceutical company, today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application to develop Pegevongitide (AV-001) for use in the acute resuscitation...
Open in Who Shared View Duplicates (20) Issue with article?

Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications Original

|
By shahid ahmad, Vice-President Operations
| Business Wire
Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics Inc., and AnGes Inc., are pleased to announce that they have entered into an agreement to expand the research indications for the Tie2 receptor agonist Pegevongitide (AV-001) currently under joint development.
Open in Who Shared View Duplicates (20) Issue with article?
See all 5 articles